2137 — Brii Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- HK$1.01bn
- -HK$1.91bn
- CNY0.62m
Annual cashflow statement for Brii Biosciences, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -521 | -1,284 | -4,191 | -490 | -184 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 421 | 394 | 3,628 | 53.5 | -305 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 25.6 | 471 | -334 | -77 | -121 |
| Change in Other Assets | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -67.3 | -404 | -879 | -496 | -594 |
| Capital Expenditures | -24.1 | 0 | -1.03 | -139 | -49.6 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -68.6 | -43.6 | -475 | -1,294 | -54.7 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -92.8 | -43.6 | -476 | -1,433 | -104 |
| Financing Cash Flow Items | -1.15 | -4.74 | -87.8 | -0.851 | -0.494 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 518 | 657 | 3,230 | -3.04 | -11 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 359 | 155 | 1,820 | -1,665 | -701 |